NCI
Geisinger MyCode Study Reveals Prevalence of Somatic Variants Linked to Rare Syndrome
Using exome sequence data for more than 163,000 Geisinger MyCode participants, researchers looked for variants in UBA1 that have been linked to VEXAS syndrome.
For proteomics firms, 2022 marked a reversal from an earlier boom, but the field pushed into emerging areas like single-cell, single-molecule, and spatial analyses.
ATCC Inks NCI Biomaterials Processing Contract
ATCC will compete to provide technical support to the the National Cancer Institute's Division of Cancer Epidemiology and Genetics Field and Biospecimen Support Services.
Researchers inside and outside the program said it has produced new methods and a wealth of data while helping to bolster proteomics' credibility.
Envisagenics Wins $2M SBIR Grant From NCI for Splicing-Based Immunotherapy Target Discovery Platform
The New York-based company said the two-year grant will help commercialize its proprietary AI drug discovery platform.